# US 2025/0368752 A1 · Monoclonal antibody against tfpi and use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0368752 A1
- Document ID: US20250368752A1
- Status: Published application
- Kind: A1
- Application number: 18/875,475
- Filed: 2023-06-05
- Published: 2025-12-04
- Earliest claimed: 2022-06-17
- Assignees: Ampsource Biopharma Shanghai Inc.
- Applicants: Ampsource Biopharma Shanghai Inc.
- Inventors: Qiang LI; Cui WU; Zhao DONG; Li ZHOU; Chi ZHOU
- Web page: https://patentgrep.com/patent/US20250368752A1

## CPC

- C07K 16/38: against protease inhibitors of peptide structure
- A61P 7/04: Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- C12N 15/85: for animal cells
- A61K 2039/505: {comprising antibodies}
- C07K 2317/14: Specific host cells or culture conditions, e.g. components, pH or temperature
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/52: Constant or Fc region; Isotype
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/567: Framework region [FR]
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Antibodies or antigen-binding fragments thereof against human TFPI are provided, along with nucleic acid molecules encoding said antibodies, expression vectors and host cells for expressing said antibodies, and methods for producing said antibodies. Furthermore, pharmaceutical compositions containing the antibody or the antigen-binding fragment thereof are provided, as well as their use in the manufacture of a medicament for the prevention and/or treatment of coagulation disorders in patients with genetic or acquired coagulation factor deficiencies.

## Claims

### Claim 1

An antibody or an antigen-binding fragment thereof capable of specifically binding to TFPI, wherein the heavy chain variable region (VH) of the antibody or the antigen-binding fragment thereof comprises at least one, two, or three complementarity-determining regions (CDRs) selected from the group consisting of:
(1) HCDR1 having a sequence as shown in SEQ ID NO: 1 or 7, or a sequence having one or several amino acid substitutions, deletions, or additions (such as 1, 2, or 3 substitutions, deletions, or additions) relative to any of the sequences;
(2) HCDR2 having a sequence as shown in SEQ ID NO: 2, 8, 12, or 13, or a sequence having one or several amino acid substitutions, deletions, or additions (such as 1, 2, or 3 substitutions, deletions, or additions) relative to any of the sequences; and
(3) HCDR3 having a sequence as shown in SEQ ID NO: 3 or 9, or a sequence having one or several amino acid substitutions, deletions, or additions (such as 1, 2, or 3 substitutions, deletions, or additions) relative to any of the sequences;
and/or, the light chain variable region (VL) of the antibody or antigen-binding fragment thereof comprises at least one, two, or three CDRs selected from the group consisting of:
(4) LCDR1 having a sequence as shown in SEQ ID NO: 4 or 10, or a sequence having one or several amino acid substitutions, deletions, or additions (such as 1, 2, or 3 substitutions, deletions, or additions) relative to any of the sequences;
(5) LCDR2 having a sequence as shown in SEQ ID NO: 5 or an amino acid sequence of Gly-Thr-Ser, or a sequence having one or several amino acid substitutions, deletions, or additions (such as 1, 2, or 3 substitutions, deletions, or additions) relative to any of the sequences; and
(6) LCDR3 having a sequence as shown in SEQ ID NO: 6, or a sequence having one or several amino acid substitutions, deletions, or additions (such as 1, 2, or 3 substitutions, deletions, or additions) relative to any of the sequences;
wherein the CDRs contained in the heavy chain variable region and/or the CDRs contained in the light chain variable region are defined by the Kabat or IMGT numbering system;
preferably, the substitutions mentioned in any one of (1)-(6) are conservative substitutions.

### Claim 2 (depends on 1)

The antibody or the antigen-binding fragment thereof according to claim 1, wherein the antibody or the antigen-binding fragment thereof comprises three VH variable region CDRs and three VL variable region CDRs selected from the following group:
(1) HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 have sequences as shown in SEQ ID NOs: 1, 2, 3, 4, 5, or 6, respectively, or sequences having one or several amino acid substitutions, deletions, or additions (such as 1, 2, or 3 substitutions, deletions, or additions) compared to any of the aforementioned sequences;
(2) HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 have sequences as shown in SEQ ID NOs: 7, 8, 9, 10, Gly-Thr-Ser, or 6, respectively, or sequences having one or several amino acid substitutions, deletions, or additions (such as 1, 2, or 3 substitutions, deletions, or additions) relative to any of the sequences;
(3) HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 have sequences as shown in SEQ ID NOs: 1, 12, 3, 4, 5, or 6, respectively, or sequences having one or several amino acid substitutions, deletions, or additions (such as 1, 2, or 3 substitutions, deletions, or additions) relative to any of the sequences;
(4) HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 have sequences as shown in SEQ ID NOs: 7, 13, 9, 10, Gly-Thr-Ser, or 6, respectively, or sequences having one or several amino acid substitutions, deletions, or additions (such as 1, 2, or 3 substitutions, deletions, or additions) relative to any of the sequences.

### Claim 3 (depends on 2)

The antibody or the antigen-binding fragment thereof according to claim 2, wherein the antibody or the antigen-binding fragment thereof is murine-derived or chimeric, wherein its heavy chain variable region comprises a heavy chain FR region of murine IgG1, IgG2, IgG3, or a variant thereof; and its light chain variable region comprises a light chain FR region of murine κ, λ chain, or a variant thereof.

### Claim 4 (depends on 3)

The antibody or the antigen-binding fragment thereof according to claim 3, wherein the antibody or the antigen-binding fragment thereof comprises the following VH and VL sequences:
the VH domain comprises an amino acid sequence as shown in SEQ ID NO: 14, or having a sequence that is substantially identical to (for example, having at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or higher identity or having one or more amino acid substitutions (such as conservative substitutions) relative to) SEQ ID NO: 14; and the VL domain comprises an amino acid sequence as shown in SEQ ID NO: 15, or having a sequence that is substantially identical to (for example, having at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or higher identity or having one or more amino acid substitutions (such as conservative substitutions) relative to) SEQ ID NO: 15.

### Claim 5 (depends on 2)

The antibody or the antigen-binding fragment thereof according to claim 2, wherein the antibody or antigen-binding fragment is humanized.

### Claim 6 (depends on 5)

The antibody or the antigen-binding fragment thereof according to claim 5, wherein the antibody or the antigen-binding fragment thereof comprises the following VH and VL sequences:
the VH domain comprises an amino acid sequence as shown in SEQ ID NO: 16, or having a sequence that is substantially identical to (for example, having at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or higher identity or having one or more amino acid substitutions (such as conservative substitutions) relative to) SEQ ID NO: 16; and the VL domain comprises an amino acid sequence as shown in SEQ ID NO: 17, or having a sequence that is substantially identical to (for example, having at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or higher identity or having one or more amino acid substitutions (such as conservative substitutions) relative to) SEQ ID NO: 17.

### Claim 7 (depends on 5)

The antibody according to claim 5, wherein the antibody comprises a heavy chain constant region and a light chain constant region derived from human immunoglobulins; preferably, the heavy chain constant region is selected from the heavy chain constant regions of human IgG1, IgG2, IgG3, and IgG4; and the heavy chain constant region has a native sequence or a sequence with one or more amino acid substitutions, deletions, or additions relative to the native sequence from which it is derived; and the light chain constant region is preferably the constant region of human κappa chain as shown in SEQ ID NO: 18.

### Claim 8 (depends on 7)

The antibody according to claim 7, wherein the heavy chain constant region contained in the antibody is selected from the following group:
(i) a heavy chain constant region of wild-type human IgG1, as shown in SEQ ID NO: 19;
(ii) a heavy chain constant region of human IgG1 containing the M252Y, S254T, T256E, and M428L mutations, as shown in SEQ ID NO: 20;
(iii) a heavy chain constant region of wild-type human IgG2, as shown in SEQ ID NO: 21;
(iv) a heavy chain constant region of human IgG4 containing an S228P mutation, as shown in SEQ ID NO: 22.

### Claim 9 (depends on 7)

The antibody according to claim 7, wherein the antibody has a heavy chain with an amino acid sequence as shown in SEQ ID NO: 23 and a light chain with an amino acid sequence as shown in SEQ ID NO: 24.

### Claim 10 (depends on 1)

The antibody or the antigen-binding fragment thereof according to claim 1, wherein the antibody or the antigen-binding fragment thereof is capable of binding to TFPI with a KD of 10 nM or lower.

### Claim 11 (depends on 1)

A DNA molecule encoding the antibody or the antigen-binding fragment thereof according to claim 1.

### Claim 12 (depends on 11)

A vector containing the DNA molecule according to claim 11.

### Claim 13 (depends on 12)

A host cell containing the vector according to claim 12, wherein the host cell comprises a prokaryotic cell, a yeast cell or a mammalian cell, preferably a CHO cell.

### Claim 14 (depends on 1)

A pharmaceutical composition comprising an antibody or the antigen-binding fragment thereof according to claim 1, and a pharmaceutically acceptable excipient, carrier, or diluent.

### Claim 15 (depends on 1)

A method for preparing an antibody or the antigen-binding fragment thereof according to claim 1, comprising: (a) obtaining a gene encoding the antibody or the antigen-binding fragment thereof and constructing an expression vector for the antibody or the antigen-binding fragment thereof; (b) transfecting the expression vector into host cells using genetic engineering methods; (c) culturing the host cells under conditions that allows the antibody or the antigen-binding fragment thereof to be produced; (d) isolating and purifying the produced antibody or antigen-binding fragment thereof;
wherein, in step (a), the expression vector is selected from one or more of plasmids, bacteria, and viruses, preferably a pcDNA3.1 vector;
wherein, in step (b), the constructed vector is transfected into the host cells using genetic engineering methods, and the host cells include a prokaryotic cells, yeast cells, or mammalian cells, preferably CHO cells;
wherein, in step (d), the antibody or the antigen-binding fragment thereof is isolated and purified using conventional immunoglobulin purification methods, including Protein A affinity chromatography and ion exchange methods.

### Claim 16 (depends on 1)

A method for prevention or treatment of diseases or events associated with inherited or acquired coagulation factor deficiencies, comprising administering to a patient in need thereof the antibody or the antigen-binding fragment thereof according to claim 1.

### Claim 17 (depends on 1)

A method for prevention or treatment of diseases or events associated with inherited or acquired coagulation factor deficiencies, comprising administering to a patient in need thereof the antibody or the antigen-binding fragment thereof according to claim 1, wherein the disease is hemophilia.
